EDIT (STOCKS)
Editas Medicine, Inc. Common Stock
$2.440000
-0.060000 (-2.40%)
Prev close: $2.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Gilmore O’Neill
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $375.21M
- Employees
- 226
- P/E (TTM)
- -2.01
- P/B (TTM)
- 55.51
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $38.69M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $147.54M |
| Nonoperating Income/Loss | -$104.00K |
| Operating Expenses | $147.54M |
| Research and Development | $80.96M |
| Other Operating Expenses | $66.58M |
| Operating Income/Loss | -$108.85M |
| Income/Loss From Continuing Operations After Tax | -$108.95M |
| Income/Loss From Continuing Operations Before Tax | -$18.12M |
| Net Income/Loss | -$108.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$108.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$108.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.17 |
| Diluted Earnings Per Share | -$1.17 |
| Basic Average Shares | 275,249,523 |
| Diluted Average Shares | 275,249,523 |
| Assets | $149.34M |
| Current Assets | $128.07M |
| Accounts Receivable | $2.59M |
| Other Current Assets | $125.47M |
| Noncurrent Assets | $21.27M |
| Fixed Assets | $2.88M |
| Other Non-current Assets | $18.39M |
| Liabilities | $144.93M |
| Current Liabilities | $39.78M |
| Accounts Payable | $4.33M |
| Wages | $2.78M |
| Other Current Liabilities | $32.67M |
| Noncurrent Liabilities | $105.15M |
| Equity | $4.41M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $4.41M |
| Liabilities And Equity | $149.34M |
| Net Cash Flow From Operating Activities | -$140.50M |
| Net Cash Flow From Operating Activities, Continuing | -$140.50M |
| Net Cash Flow From Investing Activities | $82.35M |
| Net Cash Flow From Investing Activities, Continuing | $82.35M |
| Net Cash Flow From Financing Activities | $64.90M |
| Net Cash Flow From Financing Activities, Continuing | $64.90M |
| Net Cash Flow | $6.75M |
| Net Cash Flow, Continuing | $6.75M |
| Comprehensive Income/Loss | -$108.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$109.04M |
| Other Comprehensive Income/Loss | -$55.73M |